LID.L Regulatory News (LID)

17 Jun 2005 07:00

LiDCO Group Plc17 June 2005 For Immediate Release 17th June 2005 LiDCO GROUP PLC ("LiDCO" or "the Company") Clinical Advisory Board Appointment 17th June 2005: LiDCO Group plc (AIM: LID), the cardiovascular monitoringcompany, is pleased to announce that Professor David Bennett, has joined itsClinical Advisory Board. Professor Bennett was the Director of the Intensive Care Unit, St George'sHospital for more than 25 years and is a member of the editorial board ofIntensive Care Medicine and Critical Care. One of his main research interestshas been the application of less invasive monitoring technologies to optimisecardiovascular physiology and thereby improve outcomes in critically illpatients. He was one of the (TA1) investigators using LiDCO's technology in therecently presented St George's study entitled: 'Early goal directed therapyreduces morbidity and length of hospital stay following high risk surgery.' Dr Terry O'Brien, LiDCO's Chief Executive, commented: "I am delighted to welcomeProf David Bennett to our Clinical Advisory Board. David is internationallyrenowned for his pioneering work on the application of less invasivecardiovascular monitoring to improve outcomes and reduce costs associated withthe treatment of risk surgery patients." Prof David Bennett commented: "I am very pleased to be associated with LiDCO andtheir innovative technology which facilitates the rapid and accurate assessmentof cardiac function. The use of this technology has allowed us to complete apost operative study in high risk surgery patients in whom the targeting ofoxygen delivery has led to a 40% reduction in length of hospital stay" For further information please contact: LiDCO Group PlcTerry O'Brien (CEO) terry@lidco.com 020 7749 1500Hugh McGarel-Groves (FD) hugh.mcgarel-groves@lidco.com Buchanan CommunicationsTim Anderson, Mary-Jane Johnson, James Strong 020 7466 5000 Panmure GordonGrant Harrison 020 7459 3600Marcus Jackson Notes for Editors About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base. The Company's manufacturing facility is in Hoxton, London and its currentproducts are: • LiDCOplus and PulseCO monitors: computer-based platforms for displaying arange of real-time, continuous hemodynamic parameters including cardiac output,oxygen delivery and fluid volume; • LiDCO disposables: used in conjunction with the LiDCOplus Monitoraccurately determine cardiac output in a minimally-invasive manner. Distribution Network: The Company has now achieved registration of its products in 13 markets inEurope, the USA, Brazil and Japan. It sells direct to the NHS in the UK, andthrough a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care -(EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO'sminimally invasive monitoring technology were presented during the 25thInternational Symposium on Intensive Care and Emergency Medicine in Brussels(21st to 25th March). The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000per patient. Extrapolated nationally, this would equate to a saving of £500million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significantreduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissueoxygen levels following surgery. -------------------------- (TA1) This information is provided by RNS The company news service from the London Stock Exchange